A practical reference on dual agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-17. Anything still debated is marked as such rather than presented as settled.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
=== Matsuda === The Matsuda geometry consists of an 85° electric sector, a quadrupole lens and a 72.5° magnetic sector of the same curvature direction. This geometry is used in the SHRIMP and Panorama (gas source, high-resolution, multicollector to measure isotopologues in geochemistry).
=== Tax evasion === In 2015, officials from the Directorate General of Central Excise Intelligence conducted searches at 25 locations of DS Group's companies across several states, based on gathered intelligence. The investigation revealed that fake invoices for declared goods, labelled as "sandalwood compound or oil", were issued to Messrs Dharampal Satyapal Limited through dummy factories in the Haridwar–Roorkee area, Kanpur, and Lucknow. Owners of these front supplier firms admitted to generating bills for DSL on a commission basis without manufacturing or obtaining clearance for declared goods. Allegedly, DS Group evaded taxes by claiming inadmissible Cenvat credit, totaling ₹90 crore (US$9.3 million). In 2019, the company was involved in a ₹900 crore (US$93 million) scam, which revolved around the avoidance of value-added tax (VAT) on tobacco products. According to the state Criminal Investigation Department, the directors of Dharmpal Satyapal Limited and the Gujarat trade were implicated in importing gutka and other tobacco products into the state without proper documentation, selling them in the market, and thereby avoiding the payment of VAT.
purple passion fruit (fruits of Passiflora edulis Sims) yellow passion fruit (Passiflora edulis f. flavicarpa Deg.) sweet granadilla (Passiflora ligularis) giant granadilla (Passiflora quadrangularis L.) banana passion fruit (fruits of Passiflora tarminiana)
=== Spinal nerves === A goal of spinal cord injury research is to promote neuroregeneration, reconnection of damaged neural circuits. The nerves in the spine are a tissue that requires a stem cell population to regenerate. In 2012, a Polish fireman Darek Fidyka, with paraplegia of the spinal cord, underwent a procedure, which involved extracting olfactory ensheathing cells (OECs) from Fidyka's olfactory bulbs, and injecting these stem cells, in vivo, into the site of the previous injury. Fidyka eventually gained feeling, movement and sensation in his limbs, especially on the side where the stem cells were injected; he also reported gaining sexual function. Fidyka can now drive and can now walk some distance aided by a frame. He is believed to be the first person in the world to recover sensory function from a complete severing of the spinal nerves.
=== Hub status === Air-cargo company Federal Express moved its base to Memphis from Little Rock, Arkansas, in 1973. Memphis was selected because of its temperate climate and location in the middle of the country. The decision was credited with enabling the city to go from a river port of decreasing economic relevance to an important global distribution center. Shipments flew into and out of the hub overnight on aircraft that exclusively carried cargo. To accommodate the company's rapid growth and larger aircraft, a "superhub" facility opened in 1981, featuring new methods of handling freight containers and high-speed conveyor belts operated by a computer system. Memphis became the busiest airport by cargo traffic worldwide in 1992. By 2000, the hub processed over one million packages per night, and FedEx ran 150 daily flights from Memphis. Southern Airways developed a busy operation in Memphis. In 1979, the carrier merged with North Central Airlines to form Republic Airlines, which expanded the Memphis operation into a hub in 1985. Republic began the first international flight from Memphis to Puerto Vallarta in December 1985. As of 1986, it connected the airport to 60 destinations. That year the company merged into Northwest Airlines, which maintained the hub. Northwest lost money in Memphis and nearly closed the hub in 1993. The airline then worked on its local reputation and on-time record, and passenger counts began to rise. KLM, a partner of Northwest, launched the airport's first transatlantic passenger flight to Amsterdam in June 1995.
Sources: en.wikipedia.org
==== Interferon production and signal transduction inhibition ==== The virus prevents the stimulation of type 1 IFN production and subsequent cell apoptosis in response to virus infection by inhibiting the activation of IRF-3. Two virus proteins: C and V are mainly involved in this process. SeV can attenuate cell defense mechanisms and allow itself to escape from host innate immunity by inhibiting the interferon response pathway in addition to inhibiting the interferon production. The table below demonstrates the inhibition mechanism.
=== HIV and AIDS === It has long been recognized that infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. A substantial body of evidence implicates chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency. Many now regard HIV infection not only as an evolving virus-induced immunodeficiency, but also as chronic inflammatory disease. Even after the introduction of effective antiretroviral therapy (ART) and effective suppression of viremia in HIV-infected individuals, chronic inflammation persists. Animal studies also support the relationship between immune activation and progressive cellular immune deficiency: SIVsm infection of its natural nonhuman primate hosts, the sooty mangabey, causes high-level viral replication but limited evidence of disease. This lack of pathogenicity is accompanied by a lack of inflammation, immune activation and cellular proliferation. In sharp contrast, experimental SIVsm infection of rhesus macaque produces immune activation and AIDS-like disease with many parallels to human HIV infection. Delineating how CD4 T cells are depleted and how chronic inflammation and immune activation are induced lies at the heart of understanding HIV pathogenesis—one of the top priorities for HIV research by the Office of AIDS Research, National Institutes of Health.
The two substrates of this enzyme are D-ribitol 5-phosphate and reduced nicotinamide adenine dinucleotide (NAD+). Its products are D-ribulose 5-phosphate, reduced NADH, and a proton. The enzyme can also use the alternative cofactor, nicotinamide adenine dinucleotide phosphate. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is D-ribitol-5-phosphate:NAD(P)+ 2-oxidoreductase. This enzyme is also called dehydrogenase, ribitol 5-phosphate. This enzyme participates in pentose and glucuronate interconversions.
A chaotropic agent is a molecule in water solution that can disrupt the hydrogen bonding network between water molecules (i.e. exerts chaotropic activity). This has an effect on the stability of the native state of other molecules in the solution, mainly macromolecules (proteins, nucleic acids) by weakening the hydrophobic effect. For example, a chaotropic agent reduces the amount of order in the structure of a protein formed by water molecules, both in the bulk and the hydration shells around hydrophobic amino acids, and may cause its denaturation. Conversely, an antichaotropic agent (kosmotropic) is a molecule in an aqueous solution that will increase the hydrophobic effects within the solution. Antichaotropic salts such as ammonium sulphate can be used to precipitate substances from the impure mixture. This is used in protein purification processes, to remove undesired proteins from solution.
Sources: en.wikipedia.org
== Canonical patterns == Although the evolutionary origins of the major lineages of modern cells are disputed, the primary distinctions between the three major lineages of cellular life (called domains) are firmly established. In each of these three domains, DNA replication, transcription, and translation all display distinctive features. There are three versions of ribosomal RNAs, and generally three versions of each ribosomal protein, one for each domain of life. These three versions of the protein synthesis apparatus are called the canonical patterns, and the existence of these canonical patterns provides the basis for a definition of the three domains - Bacteria, Archaea, and Eukarya (or Eukaryota) - of currently existing cells.
=== Pharmacokinetics === Orally administered endoxifen is rapidly absorbed and systemically available. The time to peak (Tmax) is between 4.5 and 6 hours after oral administration. It is not metabolized by cytochrome P450 enzymes. The half-life (t½) life of endoxifen is 52.1 to 58.1 hours.
Fospropofol (INN), often used as the disodium salt (trade name Lusedra), is an intravenous sedative-hypnotic agent. It is currently approved for use in sedation of adult patients undergoing diagnostic or therapeutic procedures such as endoscopy.
The 1st Special Forces Group is responsible for operations in the Pacific. Currently, the First Battalion is stationed at Okinawa while the 2nd, 3rd, 4th, and Group Support Battalions are stationed at Joint Base Lewis-McChord, Washington. 1st Special Forces Group's history began at Fort Bragg, NC, in 1955. Four Special Forces Operational Detachments - the 12th, 13th, 14th, and 16th - were selected from the 77th Special Forces Group and transferred to the Pacific theater over the next year. 1st Special Forces Group was officially activated at Fort Buckner, Okinawa, on 24 June 1957, with LTC A. Scott Madding as commander and MSG Robert L. Voss as the sergeant major. The 1st Special Forces Group holds the distinction of having the first and last Special Forces soldiers killed in Vietnam: Captain Harry Cramer killed 21 October 1957, and Captain Richard M. Rees killed 15 December 1973. Decades later, another 1st Special Forces Group soldier became the first American to die by hostile fire in Afghanistan: Sergeant First Class Nathan Chapman killed 2 January 2002. The 1st Special Forces Group on Okinawa was one of two Special Action Forces/Security Assistance Forces (SAF) built around Special Forces Groups. The other was built around the 8th Special Forces Group in Panama. SAF Asia was flexible and 1st Group could task organize a detachment for any time of mission in the Pacific rim. During the Vietnam War, it sent teams to Vietnam for six-month temporary duty.
The National Center for Complementary and Integrative Health (NCCIH) is a United States government agency which explores complementary and alternative medicine (CAM). It was created in 1991 as the Office of Alternative Medicine (OAM), and renamed the National Center for Complementary and Alternative Medicine (NCCAM) before receiving its current name in 2014. NCCIH is one of the 27 institutes and centers that make up the National Institutes of Health (NIH) within the United States Department of Health and Human Services. NCCIH has been criticized for funding and marketing pseudoscientific medicine and quackery.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.